Morgan Stanley’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-7,073
| Closed | -$41K | – | 6963 |
|
|
2019
Q1 | $41K | Sell |
7,073
-136,979
| -95% | -$467K | ﹤0.01% | 5759 |
|
|
2018
Q4 | $188K | Buy |
144,052
+38,803
| +37% | +$67.4K | ﹤0.01% | 5310 |
|
|
2018
Q3 | $363K | Buy |
105,249
+32,672
| +45% | +$123K | ﹤0.01% | 5165 |
|
|
2018
Q2 | $330K | Buy |
72,577
+307
| +0.4% | +$1.22K | ﹤0.01% | 5331 |
|
|
2018
Q1 | $239K | Buy |
72,270
+6,600
| +10% | +$23.4K | ﹤0.01% | 5397 |
|
|
2017
Q4 | $256K | Sell |
65,670
-68,622
| -51% | -$374K | ﹤0.01% | 5324 |
|
|
2017
Q3 | $1.39M | Buy |
134,292
+74,640
| +125% | +$734K | ﹤0.01% | 4197 |
|
|
2017
Q2 | $582K | Buy |
59,652
+41,354
| +226% | +$290K | ﹤0.01% | 4703 |
|
|
2017
Q1 | $124K | Sell |
18,298
-26,443
| -59% | -$153K | ﹤0.01% | 5522 |
|
|
2016
Q4 | $247K | Buy |
44,741
+42,063
| +1,571% | +$297K | ﹤0.01% | 5273 |
|
|
2016
Q3 | $20K | Sell |
2,678
-2,150
| -45% | -$15.7K | ﹤0.01% | 5918 |
|
|
2016
Q2 | $40K | Buy |
4,828
+4,247
| +731% | +$53K | ﹤0.01% | 5607 |
|
|
2016
Q1 | $8K | Buy |
581
+343
| +144% | +$3.96K | ﹤0.01% | 6201 |
|
|
2015
Q4 | $5K | Sell |
238
-1,697
| -88% | -$29.2K | ﹤0.01% | 6400 |
|
|
2015
Q3 | $24K | Sell |
1,935
-2,077
| -52% | -$38.9K | ﹤0.01% | 6000 |
|
|
2015
Q2 | $83K | Sell |
4,012
-51,226
| -93% | -$1.21M | ﹤0.01% | 5680 |
|
|
2015
Q1 | $1.17M | Buy |
55,238
+47,127
| +581% | +$1.23M | ﹤0.01% | 4010 |
|
|
2014
Q4 | $250K | Buy |
8,111
+7,936
| +4,535% | +$221K | ﹤0.01% | 5109 |
|
|
2014
Q3 | $3K | Buy |
+175
| New | +$2.21K | ﹤0.01% | 6426 |
|
Morgan Stanley's IMDZ Position: Q2 2019 in Review
Morgan Stanley sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 7,073 shares — an estimated $41K sold.
Morgan Stanley first reported a position in IMDZ in Q3 2014 and held it in 19 quarters. The position peaked at $1.39M in Q3 2017. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Morgan Stanley reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Morgan Stanley sold 7,073 Immune Design Corp. shares in Q2 2019, an estimated $41K.
- Morgan Stanley first reported a position in Immune Design Corp. in Q3 2014 and held it in 19 quarters.
- Morgan Stanley's Immune Design Corp. position peaked at $1.39M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Morgan Stanley's 13F filing for Q2 2019, filed 14 Aug 2019.